Correction to: Targeting of acute myeloid leukemia by five-gene engineered T cells expressing transgenic T-cell receptor specific to WT1, chimeric antigenic receptor specific to GM-CSF receptor, bispecific T-cell engager specific to CD33, and tEGFR suicide gene system
Immunotherapy Advances · 31.12.2025 · 6 (1)
DOI: 10.1093/immadv/ltag025 ↗Kurz gefasst
Korrektur in der Zeitschrift Immunotherapy Advances, online erschienen am 30.10.2026. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
(2025). Correction to: Targeting of acute myeloid leukemia by five-gene engineered T cells expressing transgenic T-cell receptor specific to WT1, chimeric antigenic receptor specific to GM-CSF receptor, bispecific T-cell engager specific to CD33, and tEGFR suicide gene system. Immunotherapy Advances, 6(1). https://doi.org/10.1093/immadv/ltag025
Vancouver
Correction to: Targeting of acute myeloid leukemia by five-gene engineered T cells expressing transgenic T-cell receptor specific to WT1, chimeric antigenic receptor specific to GM-CSF receptor, bispecific T-cell engager specific to CD33, and tEGFR suicide gene system. Immunotherapy Advances. 2025;6(1). doi:10.1093/immadv/ltag025
BibTeX
@article{euvimed2025,
title = {Correction to: Targeting of acute myeloid leukemia by five-gene engineered T cells expressing transgenic T-cell receptor specific to WT1, chimeric antigenic receptor specific to GM-CSF receptor, bispecific T-cell engager specific to CD33, and tEGFR suicide gene system},
journal = {Immunotherapy Advances},
year = {2025},
volume = {6},
number = {1},
doi = {10.1093/immadv/ltag025}
}
EUVIMED